<DOC>
	<DOCNO>NCT02377856</DOCNO>
	<brief_summary>Patients acute hepatitis C virus ( HCV ) infection usually become chronicity viremia persist 6 month infection . The result use pegylated interferon plus ribavirin combination therapy upon patient remains explore</brief_summary>
	<brief_title>Peginterferon Plus Ribavirin Combination Therapy Hepatitis C Six Months After Onset Acute Infection</brief_title>
	<detailed_description>Combination therapy pegylated interferon-alpha plus ribavirin greatly improve treatment efficacy mainstream treatment chronic hepatitis C infection . Current guideline suggest pegylated interferon monotherapy patient acute HCV infection . The efficacy might greatly improve treatment start earlier . An estimation 20 percent patient could recover acute infection spontaneously within 6 month exposure , however . The present study aim clarify efficacy pegylated interferon ribavirin combination therapy patient hepatitis C six month onset acute infection</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient 1880 year age Patients never treat traditional interferon plus ribavirin peginterferon plus ribavirin Serologic evidence chronic hepatitis C infection antiHCV antibody test Detectable serum HCVRNA &gt; 6 month Compensated liver disease Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All fertile male females receive ribavirin must use two form effective contraception treatment 6 month treatment end Women ongoing pregnancy breast feed Present therapy systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) within 6 month prior first dose study drug Any investigational drug 6 week prior first dose study drug Coinfection active hepatitis A , hepatitis B and/or human immunodeficiency virus ( HIV ) History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) Clinical evidence history hepatocellular carcinoma History evidence bleed esophageal varix condition consistent decompensated liver disease Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screen Serum creatinine level &gt; 1.5 time upper limit normal screen History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease History severe seizure disorder current anticonvulsant use History immunologically mediate disease , chronic pulmonary disease associate functional limitation , severe cardiac disease , major organ transplantation evidence severe illness , condition would make patient , opinion investigator , unsuitable study History thyroid disease poorly control prescribed medication , elevate thyroid stimulate hormone ( TSH ) concentration elevation antibody thyroid peroxidase clinical manifestation thyroid disease Evidence severe retinopathy ( e.g . CMV retinitis , macula degeneration ) Evidence drug abuse ( include excessive alcohol consumption &gt; 40 g/day ) within one year study entry Inability unwillingness provide inform consent abide requirement study Male partner woman pregnant Hgb &lt; 11 g/dL woman &lt; 12 g/dL men screen Any patient major thalassemia Patients document presumed coronary artery disease cerebrovascular disease enrol , judgment investigator , acute decrease hemoglobin 4 g/dL ( may see ribavirin therapy ) would welltolerated Local Systemic malignancy unstable status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>acute hepatitis C</keyword>
	<keyword>treatment</keyword>
	<keyword>SVR</keyword>
</DOC>